NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
Clinical Trials
29 trialsNCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT07071961 2026-02-17
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT07343791 2026-01-15
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06283134 2026-01-07
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Not yet recruiting
NCT07213570 2025-12-17
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
Phase 2 Recruiting
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03829462 2025-11-21
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Active not recruiting
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT06949982 2025-05-04
x-МАР
Pavlov First Saint Petersburg State Medical University
Phase 2 Recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated